Clinical Trial Update: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of zimberelimab and domvanalimab for non-small cell lung cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• Domvanalimab (domvanalimab)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Arcus Biosciences, Inc. | Conditions: Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING